We serve Chemical Name:methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-1-carboxylate CAS:643094-08-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-1-carboxylate
CAS.NO:643094-08-0
Synonyms:methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate;4-(METHOXYCARBONYL)NAPHTHALENE-1-BORONIC ACID,PINACOL ESTER
Molecular Formula:C18H21BO4
Molecular Weight:312.16800
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:44.76000
Exact Mass:312.15300
LogP:2.92560
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(METHOXYCARBONYL)NAPHTHALENE-1-BORONIC ACID,PINACOL ESTER physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(METHOXYCARBONYL)NAPHTHALENE-1-BORONIC ACID,PINACOL ESTER Use and application,4-(METHOXYCARBONYL)NAPHTHALENE-1-BORONIC ACID,PINACOL ESTER technical grade,usp/ep/jp grade.
Related News: The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-1-carboxylate manufacturer This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-1-carboxylate supplier Any US citizen who has been in the Hubei province in the last 14 days will be subject to up to 14 days of mandatory quarantine upon return to the United States. methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-1-carboxylate vendor No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel. methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-1-carboxylate factory No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes. methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-1-carboxylate manufacturer This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-1-carboxylate supplier Any US citizen who has been in the Hubei province in the last 14 days will be subject to up to 14 days of mandatory quarantine upon return to the United States. methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-1-carboxylate vendor No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel. methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-1-carboxylate factory No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.
